Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Recommendation of “Hold” from Brokerages

Fate Therapeutics, Inc. (NASDAQ: FATE - Get Free Report) has earned an average rating of "Hold" from the eight ratings firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and three have given a buy recommendation to the company. The